Tore Curstedt

TL;DR: The dominating functional property of pulmonary surfactant is to reduce the surface tension at the alveolar air/liquid interface, and thereby prevent the lungs from collapsing at the end of expiration, and the system exhibits host-defense properties.

TL;DR: This work hypothesizes that fusion to NT could similarly solubilize non-spidroin proteins, and design a charge-reversed mutant (NT*) that is pH insensitive, stabilized and hypersoluble compared to wild-type NT, and enables transmembrane peptide purification to homogeneity without chromatography.

TL;DR: An artificial surfactant based on SP-C33 improves Vt in immature newborn animals ventilated with standardized peak pressure but requires PEEP to build up adequate lung gas volumes.

TL;DR: After preclinical testing, CHF5633 (developed by Tore Curstedt and Jan Johansson in collaboration with Chiesi Farmaceutici) has undergone a preliminary first study in humans under the guidance of Christian Speer, and could revolutionize the treatment of preterm infants worldwide as it could be made consistently and safely in almost unlimited quantities.

TL;DR: It is concluded that the initial lung tissue association of exogenous surfactant is impaired by mechanical ventilation, associated with a reduction of dynamic compliance and evidence of increased Surfactant inactivation.